<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258855</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02498</org_study_id>
    <secondary_id>NCI-2011-02498</secondary_id>
    <secondary_id>PHII-107</secondary_id>
    <secondary_id>CHNMC-PHII-107</secondary_id>
    <secondary_id>CDR0000690654</secondary_id>
    <secondary_id>8628</secondary_id>
    <secondary_id>8628</secondary_id>
    <secondary_id>N01CM00038</secondary_id>
    <secondary_id>N01CM00070</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <secondary_id>N01CM62209</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>UM1CA186705</secondary_id>
    <nct_id>NCT01258855</nct_id>
  </id_info>
  <brief_title>Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept
      works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
      Aldesleukin may stimulate the white blood cells to kill cancer. Ziv-aflibercept may stop the
      growth of melanoma by blocking blood flow to the tumor. It is not yet known whether
      aldesleukin is more effective with or without ziv-aflibercept in treating melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Test the hypothesis that combination biotherapy with aflibercept (ziv-aflibercept) and
      high-dose (HD) interleukin (IL)-2 (aldesleukin) will improve the progression-free survival
      compared to HD IL-2 alone.

      SECONDARY OBJECTIVES:

      I. Evaluate the response rate (complete response [CR] + partial response [PR]) of aflibercept
      and HD IL-2 as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
      version 1.1 and compare to results of HD IL-2 alone.

      II. Evaluate the toxicities and tolerance of combination biotherapy with aflibercept and HD
      IL-2 and maintenance aflibercept alone in this patient population and compare to HD-IL2
      alone.

      III. Test the hypotheses related to the laboratory correlative studies. IV. Evaluate the
      overall survival of patients treated with aflibercept and HD IL-2 and HD IL-2 alone.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive ziv-aflibercept intravenously (IV) over at least 1 hour on day 1 of
      weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15
      minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only).
      Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or
      unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept
      IV on day 1. Courses repeat every 14 days in the absence of disease progression or
      unacceptable toxicity.

      ARM II: Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in
      weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3-4 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2011</start_date>
  <completion_date type="Actual">March 29, 2018</completion_date>
  <primary_completion_date type="Actual">March 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>The time from the date of randomization until date of progression, death, or recurrence, assessed up to 5 years</time_frame>
    <description>The primary comparison will be based on the log-rank test for comparison of progression-free survival, which will be estimated by the Kaplan-Meier method. Cox regression will also be conducted for progression-free survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Cox regression will be conducted for survival. Survival endpoints will be evaluated from data of randomization and will be also reported on the as-treated populations for comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival</measure>
    <time_frame>1 year</time_frame>
    <description>Cox regression will be conducted for survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate, evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Response rate will be estimated and a 95% confidence interval (CI) provided for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Toxicity will be primarily be evaluated by examining the number of doses of aldesleukin administered during the first course of combination therapy; the percentage of patients who receive all 56 doses will also be summarized. The toxicity after the scheduled 10th dose of aldesleukin, the frequency of grade III and IV toxicities, and unusual toxicities will also be summarized.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in VEGF levels</measure>
    <time_frame>Baseline up to 5 years</time_frame>
    <description>Explored using multivariate Cox regression.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage III Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIA Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIB Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIC Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IV Cutaneous Melanoma AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Arm I (ziv-aflibercept and aldesleukin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ziv-aflibercept IV over at least 1 hour in weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only). Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (aldesleukin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (ziv-aflibercept and aldesleukin)</arm_group_label>
    <arm_group_label>Arm II (aldesleukin)</arm_group_label>
    <other_name>125-L-Serine-2-133-interleukin 2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>r-serHuIL-2</other_name>
    <other_name>Recombinant Human IL-2</other_name>
    <other_name>Recombinant Human Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (ziv-aflibercept and aldesleukin)</arm_group_label>
    <arm_group_label>Arm II (aldesleukin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ziv-Aflibercept</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (ziv-aflibercept and aldesleukin)</arm_group_label>
    <other_name>AFLIBERCEPT</other_name>
    <other_name>AVE0005</other_name>
    <other_name>Eylea</other_name>
    <other_name>vascular endothelial growth factor trap</other_name>
    <other_name>VEGF Trap</other_name>
    <other_name>VEGF Trap R1R2</other_name>
    <other_name>VEGF-Trap</other_name>
    <other_name>Zaltrap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed metastatic melanoma
             (includes American Joint Committee on Cancer [AJCC] stage IV or advanced/inoperable
             stage III; also includes patients with a history of lower stage melanoma and
             subsequent recurrent metastatic disease that is either locally/regionally
             advanced/inoperable disease or distant metastases)

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;
             10 mm with computed tomography (CT) scan or clinically (must be measurable with
             calipers) according to RECIST version 1.1

          -  Patients must be free of brain metastasis by contrast-enhanced CT/magnetic resonance
             imaging (MRI) scans within 4 weeks prior to enrollment; if known to have prior brain
             metastases, must not have evidence of active brain disease after definitive therapy
             (surgery, radiation therapy, or stereotactic radiosurgery) on two successive MRI
             evaluations at least 3 months apart (one of which is =&lt; 4 weeks prior to starting the
             study drugs)

          -  A patient may be treatment na√Øve; however, up to two prior regimens for metastatic
             melanoma are allowed; prior adjuvant interferon (IFN)-alpha is allowed; no prior
             therapy with bevacizumab, aflibercept or interleukin-2 (IL-2)

          -  Patients must not have received systemic therapy or radiotherapy within the preceding
             4 weeks; patients must have recovered from adverse events due to agents administered
             more than 4 weeks earlier

          -  Patients must be at least 4 weeks from major surgery and have fully recovered from any
             effects of surgery, and be free of significant detectable infection

          -  For patients who have received prior anti-cytotoxic T-lymphocyte antigen (CTLA)4
             monoclonal antibody therapy (ipilimumab or tremelimumab), there is a risk of bowel
             perforation with IL-2 therapy; therefore, for these patients if they have a history of
             colitis or diarrhea during anti-CTLA4 monoclonal antibody therapy, they should have a
             formal evaluation by a gastroenterologist and a colonoscopy should be considered to
             demonstrate the absence of active bowel inflammation before initiating IL-2 therapy on
             this protocol

          -  Life expectancy of greater than 3 months in the opinion of the investigator

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky &gt; 70%)

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin within 1.5 x institutional upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 x institutional upper limit of normal

          -  Creatinine within 1.5 x institutional upper limit of normal OR creatinine clearance &gt;=
             60 mL/min/1.73 m^2 for patients with creatinine level above institutional normal

          -  Urine protein should be screened by urinalysis for urine protein creatinine ratio
             (UPCR); for UPCR &gt; 1, a 24-hour urine protein should be obtained and the level should
             be &lt; 500 mg

          -  Patients on full-dose anticoagulants (e.g., warfarin) with prothrombin time (PT)
             international normalized ratio (INR) &gt; 1.5 are eligible provided that both of the
             following criteria are met:

               -  The patient has an in-range INR (usually between 2 and 3) on a stable dose of
                  oral anticoagulant or on a stable dose of low molecular weight heparin

               -  The patient has no active bleeding or pathological condition that carries a high
                  risk of bleeding (e.g., tumor involving major vessels or known varices)

          -  Forced expiratory volume (FEV) 1 &gt; 2.0 liters or &gt; 75% of predicted for height and age
             (pulmonary function test [PFTs] are required for patients over 50 years old or with
             significant pulmonary or smoking history)

          -  No evidence of congestive heart failure, symptoms of coronary artery disease,
             myocardial infarction less than 6 months prior to entry, serious cardiac arrhythmias,
             or unstable angina

               -  Patients who are over 40 years old or have had previous myocardial infarction
                  greater than 6 months prior to study entry or have significant cardiac family
                  history (coronary artery disease [CAD] or serious arrhythmias) will be required
                  to have a negative or low probability cardiac stress test (for example, thallium
                  stress test, stress multi-gated acquisition scan [MUGA], stress echocardiography
                  [echo], or exercise stress test) for cardiac ischemia within 8 weeks prior to
                  registration

               -  An echocardiogram should be performed at baseline in all patients; ejection
                  fraction (EF) from baseline echocardiogram must be within the institutional
                  limits of normal as determined by the reading cardiologist; if the baseline
                  cardiac stress test incorporates an echocardiogram, then this will not need to be
                  done again at baseline

          -  No history of cerebrovascular accident or transient ischemic attacks within the past 6
             months

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for
             the duration of study participation, and for at least 6 months after completion of
             study therapy; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately

          -  Women should not be lactating and, if of childbearing age, should have a negative
             pregnancy test (beta-human chorionic gonadotropin [b-HCG] test; serum or urine,
             minimum sensitivity 25 IU/L or equivalent units of b-HCG) within two week of
             registration in the study

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Patients may not be receiving any other investigational agents

          -  Patients with brain metastases should be excluded from this clinical trial except as
             noted above

          -  Patients with known hypersensitivity to Chinese hamster ovary cell products or other
             recombinant human antibodies, and patients with a history of allergic reactions
             attributed to compounds of similar chemical or biologic composition to other agents
             used in the study

          -  Serious or non-healing wound, ulcer, or bone fracture

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 28 days of treatment

          -  Patients with the following invasive procedures:

               -  Major surgical procedures, open biopsy or significant traumatic injury within 28
                  days prior to day 1 therapy

               -  Anticipation of need for major surgical procedures during the course of the study

               -  Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
                  prior to day 1 of therapy; central venous catheter placements are permitted to be
                  completed 7 or more days prior to day 1 of therapy; however, peripherally
                  inserted central catheter (peripherally inserted central catheter [PICC] or PIC
                  line) may be placed at any time prior to or during therapy

          -  Patients with clinically significant cardiovascular or cerebrovascular disease:

               -  History of cerebrovascular accident or transient ischemic attack within past 6
                  months

               -  Uncontrolled hypertension, defined as blood pressure &gt; 150/100 mm Hg or systolic
                  blood pressure (BP) &gt; 180 mm Hg if diastolic blood pressure &lt; 90 mm Hg, on at
                  least 2 repeated determinations on separate days within past 3 months

               -  Myocardial infarction, coronary artery bypass graft (CABG) or unstable angina
                  within the past 6 Months

               -  New York Heart Association grade III or greater congestive heart failure, serious
                  cardiac arrhythmia requiring medication, unstable angina pectoris within past 6
                  months

               -  Clinically significant peripheral vascular disease within past 6 months

               -  Pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event
                  within past 6 months

          -  History of tumor-related or other serious hemorrhage, bleeding diathesis, or
             underlying coagulopathy

          -  PT INR &gt; 1.5 unless the patient is on full-dose warfarin

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible

          -  Patients who have other current malignancies are not eligible; patients with other
             malignancies are eligible if they have been continuously disease free for &gt; 5 years
             prior to the time of randomization; patients with prior history at any time of any in
             situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ,
             atypical melanocytic hyperplasia, or melanoma in situ are eligible; patients with a
             prior history of basal cell or squamous cell skin cancer are eligible; patients who
             have had multiple primary melanomas are eligible

          -  Patients must not have autoimmune disorders or conditions of immunosuppression that
             require current ongoing treatment with systemic corticosteroids (or other systemic
             immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or
             continuous use of topical steroid creams or ointments or ophthalmologic steroids or
             steroid inhalers

               -  If a patient had been taking steroids, at least 2 weeks must have passed since
                  the last dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Tarhini</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Minnesota Community Oncology Research Consortium</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2010</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

